QPPV.COM KNOWLEDGE ASSESSMENT

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Test your understanding of the concepts covered by Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information is most important to verify before interpreting a potentially important individual QTc finding?

Only the participant's treatment assignment The ECG timing, acquisition and measurement quality, correction method, baseline, heart rate and relevant clinical context Only whether the participant reported palpitations Only the maximum QTc observed in the entire study

Question 2 of 10 Which statement best describes the purpose of a traditional thorough QT/QTc study?

It directly determines whether a drug causes torsade de pointes in routine clinical use It determines whether a drug produces a threshold pharmacological effect on cardiac repolarisation It replaces all nonclinical electrophysiology studies It evaluates only symptomatic participants with structural heart disease

Question 3 of 10 Which mechanism is most directly associated with delayed ventricular repolarisation and QT prolongation in the article?

Inhibition of the rapid delayed rectifier potassium current, IKr Stimulation of skeletal-muscle sodium uptake Inhibition of gastric proton secretion Increased erythrocyte oxygen transport

Question 4 of 10 What is the most appropriate overall question for a pharmacovigilance reviewer assessing a possible drug-related QT event?

Did the QTc exceed a single universal threshold? Was the ECG abnormality reported by an automated system? What does the totality of clinical, exposure-related, pharmacological, nonclinical and patient-specific evidence indicate about proarrhythmic risk? Was the event reported after approval?

Question 5 of 10 A development team selects the QT correction formula after reviewing which formula produces the most favourable treatment result. What is the principal methodological concern?

Correction methods are interchangeable at all heart rates The correction method should be prespecified and scientifically justified because formulas behave differently, particularly at heart-rate extremes Only Bazett correction is acceptable in clinical development A correction formula is unnecessary when placebo is included

Question 6 of 10 A participant's QTc rises from 420 ms to 455 ms. Which conclusion is most appropriate based on the article?

The change proves torsade de pointes risk The change is automatically a regulatory stopping criterion The change warrants review, but interpretation requires ECG quality, timing, exposure, electrolytes, concomitant medicines and other evidence The change can be ignored because the final QTc is below 500 ms

Question 7 of 10 Why can replicate ECG measurements be particularly valuable when evaluating small QTc changes?

They eliminate the influence of heart rate They reduce random measurement variability and improve precision They prove that any observed change is treatment-related They replace the need for a predefined measurement methodology

Question 8 of 10 Why is a placebo or comparator important in population-level QTc analysis?

It guarantees that all QTc measurements are technically accurate It helps distinguish a drug-related effect from circadian, procedural, physiological and measurement variability It eliminates the need to assess drug exposure It demonstrates that any QTc change is caused by the investigational treatment

Question 9 of 10 Which ECG situation is most likely to require careful review of automated QT measurement?

A technically adequate tracing with a clear, single-peaked T wave A tracing with low-amplitude or bifid T waves, U waves, noise or an irregular rhythm A tracing collected before the first dose with no cardiac findings A tracing in which the QT interval was measured consistently using the prespecified method

Question 10 of 10 Why should ECG assessments be considered in relation to the dosing interval and pharmacokinetic exposure?

QTc effects are necessarily constant throughout the dosing interval The timing of the ECG can determine whether a concentration-related or peak effect is observed Pharmacokinetic data are relevant only to efficacy analyses Time-matched ECGs are unnecessary when a baseline ECG is available

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Cookie Settings